BGI coverage was at an average read depth of 30 and AUSCam coverage was at an average read depth of 200. Mutations were detected in LMX1B, KCNJ5, NPHP1, NPHP3, ATP6VA04, CFH and CFHR5 resulting in confirmed genetic diagnosis in 3 of 5 patients with bioinformatics completed to date. Conclusions: The promise of massively parallel sequencing click here to secure genetic diagnosis can be realised for patients with genetic renal diseases in Australian clinical practice.

Continued evolution and refinement of the local disease-targeted approach (AUSCam) continues and may result in a valuable tool for genetic diagnosis with implications for future treatment and management options. 193 CLINICAL CHARACTERISTICS AND SUPPORTIVE CARE REQUIREMENTS OF PATIENTS WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME:

A RETROSPECTIVE, SINGLE CENTRE REVIEW N ISBEL1,2, D LEARY1, S PAYNE3 1Department of Nephrology, Princess Alexandra Hospital, Brisbane, Qld; 2The University of Queensland at the Princess Alexandra Hospital, Brisbane, Qld; 3Alexion Pharmaceuticals, Australia Aim: To improve understanding supportive care requirements in aHUS patients. Background: aHUS is an ultra-rare, genetic, life threatening and complement-mediated condition associated with premature mortality and high rates of end organ damage. Patients check details were managed with plasma exchange/infusion (PE/PI), transfusions and dialysis. Despite this, 33–40% of patients die or reach end-stage kidney disease (ESKD) after their first manifestation of disease. Methods: Retrospective, de-identified data was collected for all aHUS patients consented to the global aHUS Registry and treated at Princess Alexandra Hospital (PAH) Brisbane, Australia with their first presentation of TMA between

2008 and 2012. Results: All (5) patients were female and Caucasian with a median selleck screening library age of 37 years. All patients had a clinical diagnosis of aHUS and received PE/PI for management of TMA. A mean of 234 (range 45–570) units of fresh frozen plasma (FFP) were given, 1 patient receiving 938 units of cryodepleted plasma. The median cost of FFP alone was $73,337 (range $14,103–$178,643). 60% (3/5) of patients experienced adverse events related to PE/PI. Patients were also managed with red blood cell, platelet and intravenous immunoglobulin transfusions. Eculizumab was not administered to any patient during this period. Patients were hospitalised for a median of 52 (range 4–284) days and attended a median of 64 (range 31–350) clinic appointments. All patients developed renal impairment following their first presentation, 60% of patients reached ESKD/dialysis. 80% (4/5) of patients experienced extra-renal complications of aHUS, 3 of whom experienced >1 extra-renal complication. Conclusions: Management of aHUS patients with currently available supportive care necessitates extensive utilisation of healthcare resources.